HeartSciences Inc (HSCS) Stock Analysis

AI analysis of HeartSciences Inc (HSCS)

Hold

Heart Test Laboratories Inc (HSCS) is currently not a strong buy due to its recent performance and financial instability. The stock is priced at $2.83, which is significantly below its 52-week high of $5.25, indicating a 46.5% drop from its peak. Additionally, the RSI is at 38.7, suggesting that the stock is nearing oversold territory but still lacks strong upward momentum. The company reported a gross margin of 59.06% in Q2 2026, which is positive, but it also posted a net income loss of $2.35 million in the same quarter. The primary risk is the ongoing financial losses, with a projected EPS of -0.86 for Q4 2026, indicating continued negative earnings performance. Therefore, while there are some positive indicators, the overall financial health and recent stock performance suggest holding rather than buying at this time.

Valuation Metrics

The current forward P/E ratio for HeartSciences Inc (HSCS) is 0.00, compared to its 5-year average forward P/E of -1.19.

Forward P/E

Overvalued

5Y Average P/E

-1.19

Current P/E

0.00

Overvalued

-0.26

Undervalued

-2.13

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

1.14

Current EV/EBITDA

0.00

Overvalued

6.38

Undervalued

-4.10

Forward P/S

Fair

5Y Average P/S

180.61

Current P/S

4.21

Overvalued

1071.23

Undervalued

-710.01

Alphio AI Price Scenarios for HSCS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HSCS

$5.42

Scenario price

B

Base

Base · 50%HSCS

$4.73

Scenario price

B

Bear

Bear · 25%HSCS

$4.32

Scenario price

HSCS FAQ — answered by Alphio AI

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Heart Test Laboratories Inc (HSCS) is currently not a strong buy due to its recent performance and financial instability. The stock is priced at $2.83, which is significantly below its 52-week high of $5.25, indicating a 46.5% drop from its peak. Additionally, the RSI is at 38.7, suggesting that the stock is nearing oversold territory but still lacks strong upward momentum. The company reported a gross margin of 59.06% in Q2 2026, which is positive, but it also posted a net income loss of $2.35 million in the same quarter. The primary risk is the ongoing financial losses, with a projected EPS of -0.86 for Q4 2026, indicating continued negative earnings performance. Therefore, while there are some positive indicators, the overall financial health and recent stock performance suggest holding rather than buying at this time.